CAS:PRO's ROE % is ranked better than 67.09% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs CAS:PRO: 10.71
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROE % Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROE % Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ROE % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a ROE % of 11.73% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. This is 31% below median its historical median of 17.00. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROE % has ranged from 10.68 to 28.18. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #308 out of 936 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROE % too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROE % of 11.73% is 31% below median its 10-year median of 17.00. Over the past 10 years, this metric has ranged from a low of 10.68 to a high of 28.18. The Drug Manufacturers industry median ROE % is 5.87. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 11.73% is 100% above this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #308 out of 936 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #308 out of 936 companies for ROE %. This puts PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the upper half of its industry. The industry median ROE % is 5.87. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 11.73% is 100% above this benchmark. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own ROE % has ranged from 10.68 to 28.18 over the past decade. While the company's 10-year median is 17.00 vs. the industry median of 5.87, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROE % of 11.73% is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current ROE % is 11.73%, which is 31% below median its own 10-year median of 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,327.72, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current ROE % is 11.73%, which is 31% below median its 10-year median of 17.00 and 100% above the Drug Manufacturers industry median of 5.87. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current ROE % is 11.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,327.72.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
ROE %: 11.73% (31% below median its 10-year median of 17.00)
GF Value™: MAD1,327.72 vs. price of MAD1,349.00 (1.6% above fair value)
Industry Position: 100% above the Drug Manufacturers median (#308 of 936)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score
Get the complete analysis for CAS:PRO
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
